Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (4): 338-343.DOI: 10.3969/j.issn.1673-8640.2025.04.005
Previous Articles Next Articles
CHEN Weilong, WANG Yongbing, CHEN Zegang
Received:
2024-03-31
Revised:
2025-01-17
Online:
2025-04-30
Published:
2025-05-08
CLC Number:
CHEN Weilong, WANG Yongbing, CHEN Zegang. Correlation between ZBED3,CYFRA21-1,VEGF and short-term mortality risk in patients with advanced liver cancer[J]. Laboratory Medicine, 2025, 40(4): 338-343.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.04.005
组别 | 例数 | 年龄/岁 | 性别 | 婚姻状况 | 文化水平 | ||||
---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 已婚/例 | 其他/例 | 小学及以下/例 | 初中/例 | 高中及以上/例 | |||
存活组 | 64 | 57.98±13.28 | 40 | 24 | 27 | 37 | 22 | 24 | 18 |
死亡组 | 35 | 57.63±14.88 | 18 | 17 | 18 | 17 | 10 | 16 | 9 |
统计值 | 0.122 | 1.143 | 0.779 | 0.662 | |||||
P值 | 0.903 | 0.285 | 0.377 | 0.718 | |||||
组别 | Child-Pugh 评分/分 | 肿瘤直径/cm | 体重指数/ (kg·m-2) | CYFRA21-1/(ng·mL-1) | VEGF/(pg·mL-1) | ZBED3/(pg·mL-1) | |||
存活组 | 7(5,8) | 10.5(8.1,13.3) | 23.88±1.89 | 3.34±1.10 | 96.90±29.48 | 83.09(63.50,97.90) | |||
死亡组 | 12(10,14) | 10.9(9.5,12.8) | 23.71±1.80 | 5.28±1.18 | 126.13±39.52 | 147.57(118.80,180.50) | |||
统计值 | -7.513 | -0.564 | 0.430 | -8.129 | -3.832 | -7.524 | |||
P值 | <0.001 | 0.573 | 0.668 | <0.001 | <0.001 | <0.001 | |||
组别 | 门脉癌栓/例 | 远隔转移/例 | TNM 分期 | AFP/(ng·mL-1) | PIVKAⅡ/(mAU·mL-1) | WBC计数/(×109L-1) | NLR | ||
Ⅲb期/例 | Ⅳ期/例 | ||||||||
存活组 | 34 | 35 | 45 | 19 | 509.56±62.89 | 50.83±10.22 | 12.71±1.40 | 6.66±1.75 | |
死亡组 | 13 | 18 | 19 | 16 | 617.06±54.29 | 67.87±8.76 | 14.77±1.53 | 10.15±1.26 | |
统计值 | 2.318 | 0.097 | 2.543 | -8.519 | -8.330 | -6.768 | -11.410 | ||
P值 | 0.128 | 0.756 | 0.111 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 年龄/岁 | 性别 | 婚姻状况 | 文化水平 | ||||
---|---|---|---|---|---|---|---|---|---|
男/例 | 女/例 | 已婚/例 | 其他/例 | 小学及以下/例 | 初中/例 | 高中及以上/例 | |||
存活组 | 64 | 57.98±13.28 | 40 | 24 | 27 | 37 | 22 | 24 | 18 |
死亡组 | 35 | 57.63±14.88 | 18 | 17 | 18 | 17 | 10 | 16 | 9 |
统计值 | 0.122 | 1.143 | 0.779 | 0.662 | |||||
P值 | 0.903 | 0.285 | 0.377 | 0.718 | |||||
组别 | Child-Pugh 评分/分 | 肿瘤直径/cm | 体重指数/ (kg·m-2) | CYFRA21-1/(ng·mL-1) | VEGF/(pg·mL-1) | ZBED3/(pg·mL-1) | |||
存活组 | 7(5,8) | 10.5(8.1,13.3) | 23.88±1.89 | 3.34±1.10 | 96.90±29.48 | 83.09(63.50,97.90) | |||
死亡组 | 12(10,14) | 10.9(9.5,12.8) | 23.71±1.80 | 5.28±1.18 | 126.13±39.52 | 147.57(118.80,180.50) | |||
统计值 | -7.513 | -0.564 | 0.430 | -8.129 | -3.832 | -7.524 | |||
P值 | <0.001 | 0.573 | 0.668 | <0.001 | <0.001 | <0.001 | |||
组别 | 门脉癌栓/例 | 远隔转移/例 | TNM 分期 | AFP/(ng·mL-1) | PIVKAⅡ/(mAU·mL-1) | WBC计数/(×109L-1) | NLR | ||
Ⅲb期/例 | Ⅳ期/例 | ||||||||
存活组 | 34 | 35 | 45 | 19 | 509.56±62.89 | 50.83±10.22 | 12.71±1.40 | 6.66±1.75 | |
死亡组 | 13 | 18 | 19 | 16 | 617.06±54.29 | 67.87±8.76 | 14.77±1.53 | 10.15±1.26 | |
统计值 | 2.318 | 0.097 | 2.543 | -8.519 | -8.330 | -6.768 | -11.410 | ||
P值 | 0.128 | 0.756 | 0.111 | <0.001 | <0.001 | <0.001 | <0.001 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
CYFRA21-1 | 0.868(0.798~0.938) | 4.46 ng·mL-1 | 71.4 | 82.8 | 0.542 |
VEGF | 0.720(0.604~0.835) | 140.75 pg·mL-1 | 48.6 | 95.3 | 0.439 |
ZBED3 | 0.959(0.924~0.993) | 112.69 pg·mL-1 | 82.9 | 95.3 | 0.782 |
Child-Pugh 评分 | 0.955(0.917~0.993) | 9.00 | 80.0 | 96.9 | 0.769 |
AFP | 0.893(0.831~0.955) | 594.2 ng·mL-1 | 68.6 | 90.6 | 0.592 |
PIVKAⅡ | 0.886(0.824~0.948) | 54.93 mAU·mL-1 | 100.0 | 67.2 | 0.672 |
WBC计数 | 0.818(0.734~0.902) | 14.36×109L-1 | 62.9 | 87.5 | 0.504 |
NLR | 0.897(0.939~0.981) | 8.40 | 91.4 | 82.8 | 0.742 |
项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
CYFRA21-1 | 0.868(0.798~0.938) | 4.46 ng·mL-1 | 71.4 | 82.8 | 0.542 |
VEGF | 0.720(0.604~0.835) | 140.75 pg·mL-1 | 48.6 | 95.3 | 0.439 |
ZBED3 | 0.959(0.924~0.993) | 112.69 pg·mL-1 | 82.9 | 95.3 | 0.782 |
Child-Pugh 评分 | 0.955(0.917~0.993) | 9.00 | 80.0 | 96.9 | 0.769 |
AFP | 0.893(0.831~0.955) | 594.2 ng·mL-1 | 68.6 | 90.6 | 0.592 |
PIVKAⅡ | 0.886(0.824~0.948) | 54.93 mAU·mL-1 | 100.0 | 67.2 | 0.672 |
WBC计数 | 0.818(0.734~0.902) | 14.36×109L-1 | 62.9 | 87.5 | 0.504 |
NLR | 0.897(0.939~0.981) | 8.40 | 91.4 | 82.8 | 0.742 |
指标 | β值 | 标准误 | Wald值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
AFP | 0.008 | 0.003 | 6.286 | 0.012 | 1.008(1.002~1.014) |
PIVKAⅡ | 0.037 | 0.021 | 3.094 | 0.079 | 1.037(0.996~1.081) |
WBC计数 | 0.666 | 0.162 | 16.977 | <0.001 | 1.946(1.418~2.672) |
NLR | 0.024 | 0.123 | 0.038 | 0.846 | 1.024(0.804~1.304) |
CYFRA21-1 | 0.074 | 0.182 | 0.165 | 0.685 | 1.077(0.754~1.538) |
VEGF | -0.006 | 0.005 | 1.676 | 0.195 | 0.994(0.985~1.003) |
ZBED3 | 0.027 | 0.007 | 13.621 | <0.001 | 1.028(1.013~1.042) |
Child-Pugh 评分 | 0.213 | 0.084 | 6.381 | 0.012 | 1.237(1.049~1.460) |
指标 | β值 | 标准误 | Wald值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
AFP | 0.008 | 0.003 | 6.286 | 0.012 | 1.008(1.002~1.014) |
PIVKAⅡ | 0.037 | 0.021 | 3.094 | 0.079 | 1.037(0.996~1.081) |
WBC计数 | 0.666 | 0.162 | 16.977 | <0.001 | 1.946(1.418~2.672) |
NLR | 0.024 | 0.123 | 0.038 | 0.846 | 1.024(0.804~1.304) |
CYFRA21-1 | 0.074 | 0.182 | 0.165 | 0.685 | 1.077(0.754~1.538) |
VEGF | -0.006 | 0.005 | 1.676 | 0.195 | 0.994(0.985~1.003) |
ZBED3 | 0.027 | 0.007 | 13.621 | <0.001 | 1.028(1.013~1.042) |
Child-Pugh 评分 | 0.213 | 0.084 | 6.381 | 0.012 | 1.237(1.049~1.460) |
[1] | ZAJKOWSKA M, MROCZKO B. Chemokines in primary liver cancer[J]. Int J Mol Sci, 2022, 23(16):8846. |
[2] | GUO C, LIU Z, LIN C, et al. Global epidemiology of early-onset liver cancer attributable to specific aetiologies and risk factors from 2010 to 2019[J]. J Glob Health, 2023, 13:4167. |
[3] |
GAO S, GANG J, YU M, et al. Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer[J]. BMC Cancer, 2021, 21(1):791.
DOI PMID |
[4] | CUESTA Á M, PALAO N, BRAGADO P, et al. New and old key players in liver cancer[J]. Int J Mol Sci, 2023, 24(24):17152. |
[5] | AMINI M, LOOHA M A, ZAREAN E, et al. Global pattern of trends in incidence,mortality,and mortality-to-incidence ratio rates related to liver cancer,1990-2019:a longitudinal analysis based on the global burden of disease study[J]. BMC Public Health, 2022, 22(1):604. |
[6] | 吕菁菁, 李锋, 陈思奇. 肝癌患者外周血中循环肿瘤细胞的检测及其应用探讨[J]. 中国继续医学教育, 2021, 13(8):132-135. |
[7] | 孙长杰, 舒鹏程, 彭小忠. 利用经典的ZBED3敲除鼠探索ZBED3在小鼠大脑皮质发育过程中的作用[J]. 基础医学与临床, 2020, 40(7):948-954. |
[8] | 郭飞宇, 熊书名, 高森, 等. 肿瘤组织VEGF、CD34表达联合LSM水平预测肝癌患者术后复发的价值[J]. 中国现代医学杂志, 2023, 33(16):13-19. |
[9] | 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 临床肝胆病杂志, 2015, 31(6):833-839. |
[10] | 刘炼玲, 李勇. 血清AFP-L3、CYFRA21-1及sB7-H3对原发性肝癌患者近期疗效及预后的预测价值[J]. 中西医结合肝病杂志, 2021, 31(6):502-505. |
[11] | 王斐斐, 柳仲秋, 贺启华, 等. 84例原发性肝癌患者肝动脉化疗栓塞术后预后的影响因素分析[J]. 癌症进展, 2017, 15(1):85-87. |
[12] | 张莉静, 王沛. 金属硫蛋白-3联合肿瘤标志物在原发性肝癌TACE术后疗效评估中的应用价值[J]. 医学临床研究, 2023, 40(9):1396-1399. |
[13] | HAMESCH K, GULDIKEN N, ALY M, et al. Serum keratin 19(CYFRA21-1)links ductular reaction with portal hypertension and outcome of various advanced liver diseases[J]. BMC Med, 2020, 18(1):336. |
[14] | 洪晗, 金正康, 徐小永, 等. TACE联合射频消融后复发性肝癌患者血清E-cadherin、VEGF、DKK1变化及对生存预后的影响[J]. 广西医科大学学报, 2023, 40(8):1376-1382. |
[15] | 李志路, 邱春丽, 赵勇, 等. 乐伐替尼对肝癌晚期大鼠血清b-FGF、VEGF及生存时间的影响分析[J]. 湖南师范大学学报(医学版), 2018, 15(6):106-109. |
[16] | VIZIO B, BOSCO O, DAVID E, et al. Cooperative role of thrombopoietin and vascular endothelial growth factor-A in the progression of liver cirrhosis to hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(4):1818. |
[17] | OKIKAWA S, MORINE Y, SAITO Y, et al. Inhibition of the VEGF signaling pathway attenuates tumorassociated macrophage activity in liver cancer[J]. Oncol Rep, 2022, 47(4):71. |
[18] | LACIN S, YALCIN S. The prognostic value of circulating VEGF-A level in patients with hepatocellular cancer[J]. Technol Cancer Res Treat, 2020, 19:1533033820971677. |
[19] |
LI X, HAN M, ZHANG H, et al. Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma[J]. Biomark Res, 2022, 10(1):2.
DOI PMID |
[20] | NEGI S, IMANISHI M, HAMORI M, et al. The past,present,and future of artificial zinc finger proteins:design strategies and chemical and biological applications[J]. J Biol Inorg Chem, 2023, 28(3):249-261. |
[21] | 胡炜, 邵安静, 李春霞, 等. 沉默miR-20a-5p的肝癌细胞恶性生物学行为及ZBED3、Axin蛋白表达情况观察[J]. 山东医药, 2022, 62(11):28-32. |
[22] | 胡春兰, 周龙, 田玲, 等. 高良姜素通过巨噬细胞极也及抑制锌指蛋白ZBED3诱导大鼠肝癌细胞凋亡的研究[J]. 西部医学, 2022, 34(7):973-978. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||